Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Stock: price and insider trades · China
复星医药
No insider purchase over the last 90 days. The latest, by 董晓娴, was filed 13 Sept 2022.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: what insiders have been doing
Every trade that managers of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. disclose to SSE / SZSE (CSRC) is tracked on this page. The company sits in the Health Care sector and is based in Shanghai, People's Republic of China. It was founded in 1994. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has had no insider filing for more than a year; the last one goes back to 13 September 2022.
Over the whole record (from 2022), the tally stands at 2 purchases and 1 sale.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and Vetoquinol SA. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.
Since the insiders bought
- -16.6%Entry CN¥33.76 · Close at T+365 CN¥28.16
- -16.6%Entry CN¥33.76 · Close at T+365 CN¥28.16
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 5,000 shares100.0% of flowA股XSHGSSE:173000005883199040Canonical exit: 12 Dec 2022 (T+90)
- 6,000 shares100.0% of flowA股XSHGSSE:173000005883199000Canonical exit: 12 Dec 2022 (T+90)
- 900 shares100.0% of flowA股XSHGSSE:173000006084770600
3 of 3 declarations
About Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Fosun Pharma is a Chinese company specializing in the healthcare and pharmaceutical sector. It is listed on the Shanghai Stock Exchange (XSHG).
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
